Despite delivering substantial weight loss and metabolic improvement, GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) may paradoxically reduce sexual desire and arousal in midlife women through central neuroendocrine mechanisms — specifically modulation of dopaminergic reward circuits and serotonergic signaling. This narrative review synthesizes preclinical studies, case reports, and observational data through March 2026, finding that while lifestyle interventions and bariatric surgery reliably improve female sexual function, GLP-1 therapies present an unresolved counterintuitive signal.
The clinical significance here is considerable. GLP-1 agonists are now prescribed to tens of millions of adults globally, yet female sexual health endpoints are almost universally absent from major obesity trials. The dopamine-suppression hypothesis is biologically plausible — GLP-1 receptors are expressed in mesolimbic reward regions, and appetite suppression and libido reduction may share overlapping neural substrates. This mirrors known sexual side-effect profiles of serotonergic antidepressants, suggesting a class-level vulnerability that deserves rigorous investigation.
Critical limitations apply: this is a narrative review, not a meta-analysis, and the supporting clinical evidence is largely anecdotal — case reports and small observational datasets. Confounders including menopausal hormone status, baseline depression, and relationship factors remain poorly controlled. The finding is best characterized as a credible hypothesis requiring prospective validation with validated sexual function instruments (e.g., FSFI) as pre-specified endpoints. Clinicians prescribing GLP-1 therapy to midlife women should conduct baseline sexual function assessments and monitor proactively — a standard currently absent from most clinical practice.